Understanding how specific proteins involved in cancer signaling can be targeted for treatment
Defining and targeting substrate specificity of protein tyrosine phosphatases
This study is looking at how certain proteins involved in cancer signaling, especially one called BCR-ABL, work and change the way cancer cells grow, with the hope of finding new ways to treat cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11116978 on NIH RePORTER |
What this research studies
This research investigates the role of protein tyrosine phosphatases in cancer signaling, particularly focusing on the BCR-ABL fusion protein, which is known to drive certain types of cancer. By exploring how these proteins modify signaling pathways through phosphorylation, the research aims to identify new therapeutic targets. The approach involves advanced technologies to profile phosphorylation events, which are crucial for understanding how these proteins contribute to cancer progression. Patients may benefit from insights that could lead to more effective anti-cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers associated with aberrant phosphotyrosine signaling, particularly those with BCR-ABL positive cancers.
Not a fit: Patients with cancers not related to phosphotyrosine signaling or those without the BCR-ABL fusion protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment outcomes for cancer patients.
How similar studies have performed: Previous research has shown success in targeting phosphotyrosine signaling in cancer, indicating that this approach has potential for meaningful advancements.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Hsu, Ku-Lung — University of Texas at Austin
- Study coordinator: Hsu, Ku-Lung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.